• 6131 Citations
  • 33 h-Index
1991 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

  • 6131 Citations
  • 33 h-Index
  • 118 Article
  • 6 Review article
  • 5 Letter
  • 1 Comment/debate
Filter
Article
2020

Analysis of data collected in the European Society for Blood and Marrow Transplantation (EBMT) Registry on a cohort of lymphoma patients receiving plerixafor

Sureda, A., Chabannon, C., Masszi, T., Pohlreich, D., Scheid, C., Thieblemont, C., Wahlin, B. E., Sakellari, I., Russell, N., Janikova, A., Dabrowska-Iwanicka, A., Touzeau, C., Esquirol, A., Jantunen, E., van der Werf, S., Bosman, P., Boumendil, A., Liu, Q., Celanovic, M., Montoto, S. & 1 others, Dreger, P., márc. 1 2020, In : Bone Marrow Transplantation. 55, 3, p. 613-622 10 p.

Research output: Article

2 Citations (Scopus)

Identification of the best-suited donor for generating virus-specific T cells

Tasnády, S., Karászi, É., Szederjesi, A., Bihari, G., Juhász, Z., Hardi, A., Kriván, G., Kállay, K., Reményi, P., Sinkó, J., Mikala, G., Réti, M. & Masszi, T., jan. 1 2020, In : Vox sanguinis. 115, 1, p. 18-26 9 p.

Research output: Article

Investigation of TGFB1 −1347C>T variant as a biomarker after allogeneic hematopoietic stem cell transplantation

Kövy, P., Meggyesi, N., Varga, L., Balassa, K., Bors, A., Gopcsa, L., Paksi, M., Bátai, Á., Vad, E., Sinkó, J., Tordai, A., Masszi, T., Reményi, P. & Andrikovics, H., jan. 1 2020, In : Bone Marrow Transplantation. 55, 1, p. 215-223 9 p.

Research output: Article

Results from a multicenter, noninterventional registry study for multiple myeloma patients who received stem cell mobilization regimens with and without plerixafor

Morris, C., Chabannon, C., Masszi, T., Russell, N., Nahi, H., Kobbe, G., Krejci, M., Auner, H. W., Pohlreich, D., Hayden, P., Basak, G. W., Lenhoff, S., Schaap, N., van Biezen, A., Knol, C., Iacobelli, S., Liu, Q., Celanovic, M., Garderet, L. & Kröger, N., febr. 1 2020, In : Bone Marrow Transplantation. 55, 2, p. 356-366 11 p.

Research output: Article

Open Access
1 Citation (Scopus)
2019

Calreticulin mutation specific CAL2 immunohistochemistry accurately identifies rare calreticulin mutations in myeloproliferative neoplasms

Mózes, R., Gángó, A., Sulák, A., Vida, L., Reiniger, L., Timár, B., Krenács, T., Alizadeh, H., Masszi, T., Gaál-Weisinger, J., Demeter, J., Csomor, J., Matolcsy, A., Kajtár, B. & Bödör, C., ápr. 2019, In : Pathology. 51, 3, p. 301-307 7 p.

Research output: Article

2 Citations (Scopus)

Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning

Tordai, A., Bors, A., Kiss, K. P., Balassa, K., Andrikovics, H., Batai, A., Szilvasi, A., Rajczy, K., Inotai, D., Torbagyi, E., Lengyel, L., Barta, A., Remenyi, P. & Masszi, T., jan. 1 2019, In : PloS one. 14, 6, e0218945.

Research output: Article

Open Access
3 Citations (Scopus)
1 Citation (Scopus)

Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia

on behalf of the Chronic Malignancies Working Party of the European Society for Blood Marrow Transplantation, máj. 2019, In : British Journal of Haematology. 185, 4, p. 725-732 8 p.

Research output: Article

2 Citations (Scopus)

Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients

Lovas, S., Varga, G., Farkas, P., Masszi, T., Wohner, N., Bereczki, Á., Adamkovich, N., Borbényi, Z., Szomor, Á., Alizadeh, H., Szaleczky, E., Wolf, K., Schneider, T., Plander, M., Szendrei, T., Csacsovszki, O., Csukly, Z., Rajnics, P., Egyed, M., Nagy, Z. & 4 others, Rejtő, L., Illés, Á., Mikala, G. & Váróczy, L., nov. 1 2019, In : International Journal of Hematology. 110, 5, p. 559-565 7 p.

Research output: Article

2 Citations (Scopus)
2018

Comparable results of autologous and allogeneic haematopoietic stem cell transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia in first complete molecular remission: An analysis by the Acute Leukemia Working Party of the EBMT

Giebel, S., Labopin, M., Potter, M., Poiré, X., Sengeloev, H., Socié, G., Huynh, A., Afanasyev, B. V., Schanz, U., Ringden, O., Kalhs, P., Beelen, D. W., Campos, A. M., Masszi, T., Canaani, J., Mohty, M. & Nagler, A., jún. 1 2018, In : European Journal of Cancer. 96, p. 73-81 9 p.

Research output: Article

7 Citations (Scopus)

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study

Ross, D. M., Masszi, T., Gómez Casares, M. T., Hellmann, A., Stentoft, J., Conneally, E., Garcia-Gutierrez, V., Gattermann, N., le Coutre, P. D., Martino, B., Saussele, S., Giles, F. J., Radich, J. P., Saglio, G., Deng, W., Krunic, N., Bédoucha, V., Gopalakrishna, P. & Hochhaus, A., máj. 1 2018, In : Journal of cancer research and clinical oncology. 144, 5, p. 945-954 10 p.

Research output: Article

40 Citations (Scopus)

Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies

Kiladjian, J. J., Guglielmelli, P., Griesshammer, M., Saydam, G., Masszi, T., Durrant, S., Passamonti, F., Jones, M., Zhen, H., Li, J., Gadbaw, B., Perez Ronco, J., Khan, M. & Verstovsek, S., ápr. 1 2018, In : Annals of Hematology. 97, 4, p. 617-627 11 p.

Research output: Article

7 Citations (Scopus)

Efficacy and Tolerability of a 2-Year Rituximab Maintenance Therapy in Patients with Advanced Follicular Lymphoma after Induction of Response with Rituximab-Containing First Line-Regimens (HUSOM Study)

Schneider, T., Rosta, A., Losonczy, H., Radványi, G., Ujj, G., Egyed, M., Illés, Á., Jakucs, J., Szerafin, L., Gasztonyi, Z., Masszi, T., Iványi, J., Demeter, J., Dombi, P., Tóth, A. & Borbényi, Z., ápr. 1 2018, In : Pathology and Oncology Research. 24, 2, p. 199-205 7 p.

Research output: Article

2 Citations (Scopus)

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Moskowitz, C. H., Walewski, J., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Viviani, S., Bachanova, V., Sureda, A., McClendon, T., Lee, C., Lisano, J. & Sweetenham, J., dec. 20 2018, In : Blood. 132, 25, p. 2639-2642 4 p.

Research output: Article

28 Citations (Scopus)

High dose chemotherapy and autologous stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A retrospective study by the European society for blood and marrow transplantation-lymphoma working party

Akhtar, S., Montoto, S., Boumendil, A., Finel, H., Masszi, T., Jindra, P., Nemet, D., Fuhrmann, S., Beguin, Y., Castagna, L., Ferrara, F., Capria, S., Malladi, R., Moraleda, J. M., Bloor, A., Ghesquières, H., Meissner, J., Sureda, A. & Dreger, P., jan. 2018, In : American Journal of Hematology. 93, 1, p. 40-46 7 p.

Research output: Article

6 Citations (Scopus)

Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: A study from the chronic malignancies working party of the EBMT

Gagelmann, N., Eikema, D. J., Iacobelli, S., Koster, L., Nahi, H., Stoppa, A. M., Masszi, T., Caillot, D., Lenhoff, S., Udvardy, M., Crawley, C., Arcese, W., Mariette, C., Hunter, A., Leleu, X., Schipperus, M., Delforge, M., Pioltelli, P., Snowden, J. A., Itälä-Remes, M. & 4 others, Musso, M., van Biezen, A., Garderet, L. & Kröger, N., ápr. 30 2018, In : Haematologica. 103, 5, p. 890-897 8 p.

Research output: Article

12 Citations (Scopus)

Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma

Leleu, X., Masszi, T., Bahlis, N. J., Viterbo, L., Baker, B., Gimsing, P., Maisnar, V., Samoilova, O., Rosiñol, L., Langer, C., Song, K., Izumi, T., Cleeland, C., Berg, D., Lin, H. M., Zhu, Y., Skacel, T., Moreau, P. & Richardson, P. G., aug. 2018, In : American Journal of Hematology. 93, 8, p. 985-993 9 p.

Research output: Article

18 Citations (Scopus)

Sex-specific survival difference in association with HLA-DRB1∗04 following allogeneic haematopoietic stem cell transplantation for lymphoid malignancies

Balassa, K., Andrikovics, H., Remenyi, P., Batai, A., Szilvasi, A., Bors, A., Kiss, K. P., Rajczy, K., Inotai, D., Torbagyi, E., Lengyel, L., Barta, A., Gopcsa, L., Tordai, A. & Masszi, T., jan. 2018, In : Human Immunology. 79, 1, p. 13-19 7 p.

Research output: Article

Skin-homing CD8 + T cells preferentially express GPI-anchored peptidase inhibitor 16, an inhibitor of cathepsin K

Lupsa, N., Érsek, B., Horváth, A., Bencsik, A., Lajkó, E., Silló, P., Oszvald, Á., Wiener, Z., Reményi, P., Mikala, G., Masszi, T., Buzás, E. I. & Pós, Z., dec. 2018, In : European journal of immunology. 48, 12, p. 1944-1957 14 p.

Research output: Article

2 Citations (Scopus)

The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma

Kiss, K. P., Varga, G., Mikala, G., Balassa, K., Bors, A., Kovy, P., Meggyesi, N., Kozma, A., Csacsovszki, O., Remenyi, P., Valyi-Nagy, I., Tordai, A., Masszi, T. & Andrikovics, H., márc. 4 2018, In : Leukemia and Lymphoma. 59, 3, p. 710-716 7 p.

Research output: Article

2017

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

Hájek, R., Masszi, T., Petrucci, M. T., Palumbo, A., Rosiñol, L., Nagler, A., Yong, K. L., Oriol, A., Minarik, J., Pour, L., Dimopoulos, M. A., Maisnar, V., Rossi, D., Kasparu, H., Van Droogenbroeck, J., Yehuda, D. B., Hardan, I., Jenner, M., Calbecka, M., Dávid, M. & 12 others, De La Rubia, J., Drach, J., Gasztonyi, Z., Górnik, S., Leleu, X., Munder, M., Offidani, M., Zojer, N., Rajangam, K., Chang, Y. L., San-Miguel, J. F. & Ludwig, H., jan. 1 2017, In : Leukemia. 31, 1, p. 107-114 8 p.

Research output: Article

64 Citations (Scopus)

Carfilzomib-lenalidomide-dexamethasone vs lenalidomide- dexamethasone in relapsed multiple myeloma by previous treatment

Dimopoulos, M. A., Stewart, A. K., Masszi, T., Spicka, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A., San-Miguel, J., Ludwig, H., Ro, S., Aggarwal, S., Moreau, P. & Palumbo, A., jan. 1 2017, In : Blood Cancer Journal. 7, 4, e554.

Research output: Article

27 Citations (Scopus)

Impact of prior therapy on the efficacy and safety of oral ixazomiblenalidomide-dexamethasone vs. Placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1

Mateos, M. V., Masszi, T., Grzasko, N., Hansson, M., Sandhu, I., Pour, L., Viterbo, L., Jackson, S. R., Stoppa, A. M., Gimsing, P., Hamadani, M., Borsaru, G., Berg, D., Lin, J., Di Bacco, A., Van De Velde, H., Richardson, P. G. & Moreau, P., szept. 30 2017, In : Haematologica. 102, 10, p. 1767-1775 9 p.

Research output: Article

23 Citations (Scopus)

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients

Avet-Loiseau, H., Bahlis, N. J., Chng, W. J., Masszi, T., Viterbo, L., Pour, L., Ganly, P., Palumbo, A., Cavo, M., Langer, C., Pluta, A., Nagler, A., Kumar, S., Ben-Yehuda, D., Rajkumar, S. V., San-Miguel, J., Berg, D., Lin, J., Van De Velde, H., Esseltine, D. L. & 3 others, di Bacco, A., Moreau, P. & Richardson, P. G., dec. 14 2017, In : Blood. 130, 24, p. 2610-2618 9 p.

Research output: Article

38 Citations (Scopus)

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

Kumar, S., Moreau, P., Hari, P., Mateos, M. V., Ludwig, H., Shustik, C., Masszi, T., Spencer, A., Hájek, R., Romeril, K., Avivi, I., Liberati, A. M., Minnema, M. C., Einsele, H., Lonial, S., Berg, D., Lin, J., Gupta, N., Esseltine, D. L. & Richardson, P. G., aug. 2017, In : British Journal of Haematology. 178, 4, p. 571-582 12 p.

Research output: Article

28 Citations (Scopus)

Proteasome Subunit Beta Type 1 P11A Polymorphism Is a New Prognostic Marker in Multiple Myeloma

Varga, G., Mikala, G., Kiss, K. P., Kosóczki, É., Szabó, E., Meggyesi, N., Balassa, K., Kövy, P., Tegze, B., Szombath, G., Tordai, A., Andrikovics, H., Homolya, L. & Masszi, T., nov. 2017, In : Clinical Lymphoma, Myeloma and Leukemia. 17, 11, p. 734-742 9 p.

Research output: Article

1 Citation (Scopus)
2016

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): And randomised, phase 3, open-label, multicentre study

Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hájek, R., Facon, T., Ludwig, H., Oriol, A., Goldschmidt, H., Rosiñol, L., Straub, J., Suvorov, A., Araujo, C., Rimashevskaya, E., Pika, T., Gaidano, G., Weisel, K., Goranova-Marinova, V., Schwarer, A. & 11 others, Minuk, L., Masszi, T., Karamanesht, I., Offidani, M., Hungria, V., Spencer, A., Orlowski, R. Z., Gillenwater, H. H., Mohamed, N., Feng, S. & Chng, W. J., jan. 1 2016, In : The Lancet Oncology. 17, 1, p. 27-38 12 p.

Research output: Article

393 Citations (Scopus)

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma

Avet-Loiseau, H., Fonseca, R., Siegel, D., Dimopoulos, M. A., Špička, I., Masszi, T., Hájek, R., Rosiñol, L., Goranova-Marinova, V., Mihaylov, G., Maisnar, V., Mateos, M. V., Wang, M., Niesvizky, R., Oriol, A., Jakubowiak, A., Minarik, J., Palumbo, A., Bensinger, W., Kukreti, V. & 4 others, Ben-Yehuda, D., Stewart, A. K., Obreja, M. & Moreau, P., szept. 1 2016, In : Blood. 128, 9, p. 1174-1180 7 p.

Research output: Article

65 Citations (Scopus)

Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapy

Mesa, R., Verstovsek, S., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Zhen, H., Jones, M. M., Parasuraman, S., Li, J., Côté, I., Habr, D. & Vannucchi, A. M., aug. 1 2016, In : European journal of haematology. 97, 2, p. 192-200 9 p.

Research output: Article

25 Citations (Scopus)

Co-occurrence of myeloproliferative neoplasms and solid tumors is attributed to a synergism between cytoreductive therapy and the common TERT polymorphism rs2736100

Krahling, T., Balassa, K., Kiss, K. P., Bors, A., Batai, A., Halm, G., Egyed, M., Fekete, S., Remenyi, P., Masszi, T., Tordai, A. & Andrikovics, H., jan. 2016, In : Cancer Epidemiology Biomarkers and Prevention. 25, 1, p. 98-104 7 p.

Research output: Article

15 Citations (Scopus)

Daratumumab, bortezomib, and dexamethasone for multiple myeloma

Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M., Spicka, I., Hungria, V., Munder, M., Mateos, M. V., Mark, T. M., Qi, M., Schecter, J., Amin, H., Qin, X., Deraedt, W., Ahmadi, T., Spencer, A. & Sonneveld, P., aug. 25 2016, In : New England Journal of Medicine. 375, 8, p. 754-766 13 p.

Research output: Article

559 Citations (Scopus)

Early versus delayed autologous stem cell transplantation and interferon maintenance in multiple myeloma: Single-center experience of 18 years

Remenyi, P., Varga, G., Mikala, G., Reti, M., Gopcsa, L., Batai, A., Csukly, Z., Lengyel, L., Torbagyi, E., Barta, A., Fabian, J., Levai, D., Szombath, G., Andrikovics, H. & Masszi, T., jan. 1 2016, In : Transplantation Proceedings. 48, 1, p. 177-184 8 p.

Research output: Article

9 Citations (Scopus)

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: Results from the European ENEST1st study

Hochhaus, A., Rosti, G., Cross, N. C. P., Steegmann, J. L., Le Coutre, P., Ossenkoppele, G., Petrov, L., Masszi, T., Hellmann, A., Griskevicius, L., Wiktor-Jedrzejczak, W., Rea, D., Coriu, D., Brümmendorf, T. H., Porkka, K., Saglio, G., Gastl, G., Müller, M. C., Schuld, P., Di Matteo, P. & 5 others, Pellegrino, A., Dezzani, L., Mahon, F. X., Baccarani, M. & Giles, F. J., jan. 1 2016, In : Leukemia. 30, 1, p. 57-64 8 p.

Research output: Article

63 Citations (Scopus)

Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in patientswith relapsed multiple myeloma

Stewart, A. K., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Buchanan, J., Cocks, K., Yang, X., Xing, B., Zojwalla, N., Tonda, M., Moreau, P. & Palumbo, A., nov. 10 2016, In : Journal of Clinical Oncology. 34, 32, p. 3921-3930 10 p.

Research output: Article

37 Citations (Scopus)

Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia

Mátrai, Z., Andrikovics, H., Szilvási, A., Bors, A., Kozma, A., Ádám, E., Halm, G., Karászi, É., Tordai, A. & Masszi, T., okt. 18 2016, (Accepted/In press) In : Pathology and Oncology Research. p. 1-7 7 p.

Research output: Article

3 Citations (Scopus)

Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma

TOURMALINE-MM1 Study Group, ápr. 28 2016, In : New England Journal of Medicine. 374, 17, p. 1621-1634 14 p.

Research output: Article

459 Citations (Scopus)

Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma

Ramsey, S. D., Nademanee, A., Masszi, T., Holowiecki, J., Abidi, M., Chen, A., Stiff, P., Viviani, S., Sweetenham, J. W., Radford, J., Zhu, Y., Bonthapally, V., Thomas, E., Richhariya, A., Hunder, N. N., Walewski, J. & Moskowitz, C. H., dec. 1 2016, In : British Journal of Haematology. 175, 5, p. 860-867 8 p.

Research output: Article

10 Citations (Scopus)

Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

Balassa, K., Krahling, T., Remenyi, P., Batai, A., Bors, A., Kiss, K. P., Torbagyi, E., Gopcsa, L., Lengyel, L., Barta, A., Varga, G., Tordai, A., Masszi, T. & Andrikovics, H., júl. 7 2016, (Accepted/In press) In : Leukemia and Lymphoma. p. 1-8 8 p.

Research output: Article

4 Citations (Scopus)

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: A new classification from the European Society for Blood and Marrow Transplantation

Mohty, M., Malard, F., Abecassis, M., Aerts, E., Alaskar, A. S., Aljurf, M., Arat, M., Bader, P., Baron, F., Bazarbachi, A., Blaise, D., Ciceri, F., Corbacioglu, S., Dalle, J. H., Dignan, F., Fukuda, T., Huynh, A., Masszi, T., Michallet, M., Nagler, A. & 12 others, NiChonghaile, M., Okamoto, S., Pagliuca, A., Peters, C., Petersen, F. B., Richardson, P. G., Ruutu, T., Savani, B. N., Wallhult, E., Yakoub-Agha, I., Duarte, R. F. & Carreras, E., júl. 1 2016, In : Bone Marrow Transplantation. 51, 7, p. 906-912 7 p.

Research output: Article

120 Citations (Scopus)

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial

Verstovsek, S., Vannucchi, A. M., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Kirito, K., Besses, C., Hino, M., Moiraghi, B., Miller, C. B., Cazzola, M., Rosti, V., Blau, I., Mesa, R., Jones, M. M., Zhen, H. & 4 others, Li, J., Francillard, N., Habr, D. & Kiladjian, J. J., jan. 1 2016, In : Haematologica. 101, 7, p. 821-829 9 p.

Research output: Article

76 Citations (Scopus)
2015

A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

Orlowski, R. Z., Gercheva, L., Williams, C., Sutherland, H., Robak, T., Masszi, T., Goranova-Marinova, V., Dimopoulos, M. A., Cavenagh, J. D., Špička, I., Maiolino, A., Suvorov, A., Bladé, J., Samoylova, O., Puchalski, T. A., Reddy, M., Bandekar, R., van de Velde, H., Xie, H. & Rossi, J. F., jan. 1 2015, In : American Journal of Hematology. 90, 1, p. 42-49 8 p.

Research output: Article

74 Citations (Scopus)

Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II BELIEF (CLN-19) study

O'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., Bhat, G., Choi, M. R., Walewski, J., Savage, K., Foss, F., Allen, L. F. & Shustov, A., aug. 10 2015, In : Journal of Clinical Oncology. 33, 23, p. 2492-2499 8 p.

Research output: Article

190 Citations (Scopus)

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up

Ludwig, H., Greil, R., Masszi, T., Spicka, I., Shpilberg, O., Hajek, R., Dmoszynska, A., Paiva, B., Vidriales, M. B., Esteves, G., Stoppa, A. M., Robinson, D., Chaturvedi, S., Ataman, O., Enny, C., Feng, H., van de Velde, H. & Viterbo, L., nov. 2015, In : British Journal of Haematology. 171, 3, p. 344-354 11 p.

Research output: Article

18 Citations (Scopus)

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial

Moskowitz, C. H., Nademanee, A., Masszi, T., Agura, E., Holowiecki, J., Abidi, M. H., Chen, A. I., Stiff, P., Gianni, A. M., Carella, A., Osmanov, D., Bachanova, V., Sweetenham, J., Sureda, A., Huebner, D., Sievers, E. L., Chi, A., Larsen, E. K., Hunder, N. N. & Walewski, J., máj. 9 2015, In : The Lancet. 385, 9980, p. 1853-1862 10 p.

Research output: Article

350 Citations (Scopus)

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma

ASPIRE Investigators, jan. 8 2015, In : New England Journal of Medicine. 372, 2, p. 142-152 11 p.

Research output: Article

663 Citations (Scopus)

NFKB1 -94ins/delATTG polymorphism is a novel prognostic marker in first line-treated multiple myeloma

Varga, G., Mikala, G., Andrikovics, H., Koszarska, M., Balassa, K., Ádám, E., Kozma, A., Tordai, A. & Masszi, T., márc. 1 2015, In : British Journal of Haematology. 168, 5, p. 679-688 10 p.

Research output: Article

8 Citations (Scopus)

Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors

Khoury, H. J., Cortes, J., Baccarani, M., Wetzler, M., Masszi, T., Digumarti, R., Craig, A., Benichou, A. C. & Akard, L., jan. 1 2015, In : Leukemia and Lymphoma. 56, 1, p. 120-127 8 p.

Research output: Article

14 Citations (Scopus)

Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia

Stone, R. M., Mazzola, E., Neuberg, D., Allen, S. L., Pigneux, A., Stuart, R. K., Wetzler, M., Rizzieri, D., Erba, H. P., Damon, L., Jang, J. H., Tallman, M. S., Warzocha, K., Masszi, T., Sekeres, M. A., Egyed, M., Horst, H. A., Selleslag, D., Solomon, S. R., Venugopal, P. & 2 others, Lundberg, A. S. & Powell, B., márc. 20 2015, In : Journal of Clinical Oncology. 33, 11, p. 1252-1257 6 p.

Research output: Article

36 Citations (Scopus)

Ruxolitinib versus standard therapy for the treatment of polycythemia vera

Vannucchi, A. M., Kiladjian, J. J., Griesshammer, M., Masszi, T., Durrant, S., Passamonti, F., Harrison, C. N., Pane, F., Zachee, P., Mesa, R., He, S., Jones, M. M., Garrett, W., Li, J., Pirron, U., Habr, D. & Verstovsek, S., jan. 1 2015, In : New England Journal of Medicine. 372, 5, p. 426-435 10 p.

Research output: Article

292 Citations (Scopus)

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial

Pardanani, A., Harrison, C., Cortes, J. E., Cervantes, F., Mesa, R. A., Milligan, D., Masszi, T., Mishchenko, E., Jourdan, E., Vannucchi, A. M., Drummond, M. W., Jurgutis, M., Kuliczkowski, K., Gheorghita, E., Passamonti, F., Neumann, F., Patki, A., Gao, G. & Tefferi, A., aug. 1 2015, In : JAMA oncology. 1, 5, p. 643-651 9 p.

Research output: Article

117 Citations (Scopus)